Faculty Summaries
Elizabeth Hopper-Borge, PhD
Elizabeth Hopper-Borge, PhD
Assistant Professor
Elizabeth.Hopper@fccc.edu
Office Phone: 215-214-1505
Lab Phone: 215-214-3757
Fax: 215-728-3616
Office: W463

Publications

  • Malofeeva EV, Domanitskaya N, Gudima M, Hopper-Borge EA. Modulation of the ATPase and transport activities of broad specificity multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67. PubMed
  • Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, Kuang Y, Grinberg A, Westphal H, Chen ZS, Klein-Szanto AJ, Belinsky MG, Kruh GD. Contribution of Abcc10 (Mrp7) to In Vivo Paclitaxel Resistance as Assessed in Abcc10-/- Mice. Cancer Res. 2011 May 15;71(10):3649-3657. PubMed
  • Pushpakom SP, Liptrott NJ, Rodríguez-Nóvoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Bonora S, Di Perri G, Back DJ, Khoo S, Pirmohamed M, Owen A. Genetic variants of ABCC10, a novel tenofovir. J Infect Dis. 2011 Jul;204(1):145-53. PubMed
  • Shen T, Kuang YH, Ashby CR, Lei Y, Chen A, Zhou Y, Chen X, Tiwari AK, Hopper-Borge E, Ouyang J, Chen ZS. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One. 2009 Oct 20;4(10):e7520. PubMed
  • Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee JW, Fu LW, Chen ZS. Lapatinib and erlotinib are potent reveral agents for MPR7 ( ABCC10) mediated multidrug resistance. Biochem Pharmacol. 2009 Aug 29. In press
  • Hopper-Borge E, Nasto RN, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Exp Opin Ther Targets. 2009;13(3):339-362. PubMed
  • Zhou Y, Hopper-Borge E, Shi Z, Shen T, Furukawa T, Akiyama S, Peng XX, Huang XC, Ashby C, Kruh GD, Chen ZS. Cepharanthine is a potent reversal agent for MRP7-mediated multidrug resistance. Biochem Pharmacol. 2009;77:993-1001. PubMed
  • Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009;69:178-184. PubMed
  • Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Luduena RF, Kruh GD, Mooberry SL. The taccolonides: microtubule stabilizers that circumvent clinically relevant taxane resistant mechanisms. Cancer Res. 2008;68:8881-88.
  • Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10 (MRP7), ABCC11 (MRP8) and ABCC12 (MRP9). Pflugers Arch.-Eur. J. Physiol. 2007;453:675-684. PubMed
  • Hopper-Borge E, Chen Z-S, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of MRP7 (ABCC10): resistance to docetaxel. Cancer Res. 2004;64:4927-30. PubMed
  • Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD. MRP8 (ABCC11) is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines, 2'3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)-adenine. J Biol Chem. 2003;278:29509-14. PubMed
  • Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003;63:351-358. PubMed
  • Shen H, Chen ZJ, Zilfou JT, *Hopper E, *Murphy M, Tew KD. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J. Pharmacol. Exp. Ther. 2001;297:1067-073,. *These authors contributed equally. PubMed
  • Hopper E, Belinsky M, Zeng H, Tosolini A, Testa J, Kruh G. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Letters. 2001;162:181-191.
  • Bell C, Budarf B, Nieuwenhuijsen P, Desjardins E, Hopper E, Valmiki V, Emanuel B et al. Integration of physical breakpoint and genetic maps of chromosome 22. Localization of 587 yeast artificial chromosomes with 238 mapped markers. Hum Mol Genet. 1995;4:59-69.